DexCom, Inc. has appointed Rick Osterloh to its Board of Directors as part of a strategic push to enhance its market presence, coinciding with the increasing adoption of its continuous glucose monitoring systems among GLP-1 drug users. The company is set to lead the market with its upcoming 15-day G7 CGM system while maintaining a positive financial outlook, reaffirming 2026 revenue guidance of $5.16–$5.25 billion. Despite trading 14% below analyst consensus, market confidence remains strong, with updated price targets reflecting the company's projected growth towards $6.5 billion in revenue by 2028.
“DexCom, Inc. · appointed · Rick Osterloh · to its Board of Directors”
“Dexcom · has pioneered · glucose biosensing technology · for more than 25 years”
“DexCom · is seeing · higher adoption of its continuous glucose monitoring systems · among patients using GLP-1 drugs”
“The company · is refining · its product lineup · expecting the 15 day G7 CGM system to take a leading role”
“DexCom · focuses on · continuous glucose monitoring solutions · that help people track blood sugar levels in real time”
“DexCom · trades about · 14% below consensus · with a price of US$73.07 versus an average analyst target of US$85.46”
“DexCom’s P/E · is · 33.6 · relative to the medical equipment industry average of about 30.8”
“DexCom Inc · saw · new options · available for the March 2027 expiration”
“DexCom, Inc. · will present an update on the company · 47th Annual Raymond James Institutional Investors Conference · March 2, 2026”
“DexCom, Inc. · has been pioneering glucose biosensing for · more than 25 years · since 1999”
“DexCom, Inc. (NASDAQ:DXCM) · is one of · the 10 best healthcare equipment stocks to buy · according to hedge funds”
“William Plovanic · reduced the price target on · DexCom, Inc. (NASDAQ:DXCM) · from $99 to $95”
.jpg&width=160)